The company is a blockchain conversational AI platform that performs deep learning computations on quantified biology to develop predictive analytics and personal health insights.

The solution's technology is designed to provide patients with a robo-doctor that guides them to collect their full biological profiles and receive insights based on their data. At the patients-user's discretion and via a crypto wallet the data is structured to be shared with AI researchers and data scientists to work on new predictive models. 

With its first customers on board and the use of the blockchain technology to timestamp its datasets and decentralize its AI, well positioned to bring unmatched benefits to patients, providers and payers.

How we work with DLA Piper

When's founders were looking to start their venture, they engaged DLA Piper at the pre-formation stage to optimize the corporate form, build a team, protect IP, get financed and scale for growth. Most recently, with DLA Piper's guidance, completed a transaction involving the sale of simple agreements for future tokens (SAFTs), which are convertible into digital tokens named neurons. The sale was a private placement in compliance with applicable securities laws to verified accredited investors who have either helped support in the past or have demonstrated the desire to partner and support the network of digital tokens.